Newsroom | 53552 results

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-212 for the treatment of patients with metastatic castration-resistant prostate cancer (m...

SAN FRANCISCO--(BUSINESS WIRE)--The Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF) today announced it has been awarded a $46 million grant from Aligning Research to Impact Autism (ARIA) to expand its landmark research into the molecular mechanisms underlying autism spectrum disorder (ASD). The funding directly builds on a study published today in Science (DOI: 10.1126/science.ady4523) in which UCSF scientists at QBI and the Department of Psychiatr...

WATERTOWN, Mass.--(BUSINESS WIRE)--Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson’s disease and other neurodegenerative disorders, today announced the appointment of Kenny Choi, Ph.D., as Chief Technical Officer (CTO). Dr. Choi will lead Oryon’s technical operations and Chemistry, Manufacturing, and Controls (CMC) strategy, including transfer of the manufacturing process for the company’s autolog...

CAMBRIDGE, England & NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--Mission Therapeutics, a clinical-stage biotechnology company developing first-in-class therapeutics that enhance mitophagy to protect cell and organ health and NeuraLight, a leader in precision brain function measures, today announced a partnership to deploy NeuraLight's brain function biomarker assessments across Mission's multinational trial of MTX325 in Parkinson's disease. MTX325 is a first-in-class, orally bioavailable and...

VALHALLA, N.Y.--(BUSINESS WIRE)--FUJIFILM Holdings America Corporation (FUJIFILM Americas) today announced the leadership appointment of Michael (Mike) J. Hartman as Vice President, General Counsel and Secretary, effective August 24. This new appointment strengthens the leadership team for FUJIFILM Americas regional headquarters, which represents more than 20 subsidiaries across the United States, Canada, Brazil, and Colombia. “We are very pleased to welcome Mike to Fujifilm’s executive leaders...

MIAMI & LEAWOOD, Kan.--(BUSINESS WIRE)--The American Medical Society for Sports Medicine (AMSSM) and OpenEvidence today announced a partnership that will focus on co-developing AI-powered educational resources on sports medicine for both patients and clinicians. This exclusive collaboration brings the expertise of AMSSM’s sports medicine physicians to OpenEvidence, the leading AI-powered clinical decision support platform, and will build on the AMSSM’s robust foundation of educational materials....

BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) has announced the launch of the Medifast Metabolic Health Institute, established to advance metabolic health through rigorous research and credible, evidence-based education. The institute brings Medifast’s clinical research, scientific expertise, and educational resources under a single body, solidifying the company’s position in the metabolic health space. It follows the July launch of Trilivy™, which replaced OPTAVIA® as the company’s co...

PHILADELPHIA--(BUSINESS WIRE)--iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis (EoE) showed that AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and clinically meaningful improvements across both co-primary and all key secondary endpoints at week 24, which were sustained through week 52 in both doses tested. The co-primary endpoints were histologic remission and the frequency and severity of...